AlphaTON Capital Corp.

Portage Biotech Inc. is a biotechnology company focused on discovering and developing innovative therapies for immune-oncology and cancer treatment. The primary aim of Portage is to investigate and harness the potential of the human immune system to fight cancer. Portage Biotech operates by leveraging its expertise in immunology to advance a diverse pipeline of early-stage development programs and proprietary platforms that target cancerous cells with minimal impact on healthy tissues. The company's innovative approach involves developing unique co-stimulatory molecules and immune enhancers that can be integrated into oncology therapeutics. By focusing on novel treatments and collaborative partnerships with research institutions and pharmaceutical companies, Portage Biotech aims to accelerate the delivery of promising cancer therapies to the market. Through innovation and strategic development, Portage plays a significant role in the pharmaceutical sector, particularly within the biopharmaceutical niche dedicated to oncology, positioning itself as a key player in the advancement of cutting-edge cancer treatment solutions.